当前位置: X-MOL 学术Lancet › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1/2 clinical trial.
The Lancet ( IF 98.4 ) Pub Date : 2017-09-01 , DOI: 10.1016/s1474-4422(17)30169-2
Marc Tardieu , Michel Zérah , Marie-Lise Gougeon , Jérome Ausseil , Stéphanie de Bournonville , Béatrice Husson , Dimitrios Zafeiriou , Giancarlo Parenti , Philippe Bourget , Béatrice Poirier , Valérie Furlan , Cécile Artaud , Thomas Baugnon , Thomas Roujeau , Ronald G Crystal , Christian Meyer , Kumaran Deiva , Jean-Michel Heard

Mucopolysaccharidosis type IIIB syndrome (also known as Sanfilippo type B syndrome) is a lysosomal storage disease resulting in progressive deterioration of cognitive acquisition after age 2-4 years. No treatment is available for the neurological manifestations of the disease. We sought to assess the safety and efficacy of a novel intracerebral gene therapy.

中文翻译:

脑内基因治疗儿童黏多糖贮积症IIIB型综合征:一项未经控制的1/2期临床试验。

粘多糖贮积症IIIB型综合征(也称为Sanfilippo B型综合征)是一种溶酶体贮积病,会导致2-4岁后认知能力的逐渐恶化。没有针对该疾病的神经学表现的治疗方法。我们试图评估一种新型脑基因治疗的安全性和有效性。
更新日期:2017-08-10
down
wechat
bug